Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate
This article was originally published in The Tan Sheet
Executive Summary
Ongoing studies of Bristol-Myers Squibb's newly approved Vaniqa prescription hair removal drug could broaden the topical cream's target population to include men. FDA approved the product for removal of women's facial hair July 27.
You may also be interested in...
OTC Vaniqa Could Surface By Early 2005
Women First HealthCare may explore Rx-to-OTC switch opportunities forVaniqa facial hair growth retardation cream as early as 2004, the firm stated
OTC Vaniqa Could Surface By Early 2005
Women First HealthCare may explore Rx-to-OTC switch opportunities forVaniqa facial hair growth retardation cream as early as 2004, the firm stated
BMS Mead Johnson Impending Changes Continue Reorganization Efforts
An organizational shakeup at Mead Johnson is being executed by parent Bristol-Myers Squibb to help reverse disappointing results in recent quarters at the nutritionals division.